Venture capital firm a16z is doubling down on Stipple Bio, a biotech startup focused on a new frontier in oncology drug development. The investment underscores a growing trend in biotech startup funding, where precision is paramount.
Paul Ehrlich's century-old dream of "aiming chemically" to separate drug efficacy from collateral damage remains a core challenge in oncology drug development. While advancements like CAR-Ts and antibody-drug conjugates have improved tumor specificity, "on-target, off-tumor" toxicities still limit treatment effectiveness and patient tolerance.
Stipple Bio, co-founded by Aaron Ring and Aashish Manglik, seeks to address this by defining tumor specificity at the epitope level, not just RNA or protein expression. They are developing an "epitomics" platform, dubbed Pointillist, to discover unique pathological epitopes on cancer cells.
This platform aims to map tumor biology in unprecedented detail. It could pave the way for a new generation of epitope-targeted biologic therapies.
As Stipple Bio approaches clinical-stage status with its first lead drug candidate, the continued investment from a16z signals confidence in its approach to precision medicine.